Is INBS a good stock to purchase?

**Intelligent Bio Solutions Inc. (INBS) does not appear to be a good stock to purchase at this time.** Here's why:

1. **Financial Performance**: INBS has reported a net loss of $2.99 million and a diluted EPS of -$1.43 for the most recent quarter. The company's net income has decreased by 78% year-on-year, and total revenue has increased by 1,032.26% compared to the previous year. While the revenue growth is impressive, the net loss indicates that the company is currently unprofitable.

|Ticker|Name|Total Revenue|Net Income|Diluted EPS|Date|code|market_code|
|---|---|---|---|---|---|---|---|
|INBS.O|Intelligent Bio|907642|-2986765|-1.43|2024 Q3|INBS|186|

2. **Valuation Metrics**: INBS's price-to-book ratio is 0.34, which is relatively low, suggesting that the stock may be undervalued based on its assets. The company's price-to-sales ratio is 1.04, which is moderate, and the price-to-earnings ratio (TTM) is -0.38, which is negative and indicates that the company is not generating profits.

|Ticker|Name|Price to Book Ratio|P/S|P/E(TTM)|Date|code|market_code|
|---|---|---|---|---|---|---|---|
|INBS.O|Intelligent Bio||1.0358302753990114|-0.375981|20240806|INBS|186|
|INBS.O|Intelligent Bio|0.3360|||20240807|INBS|186|

3. **Free Cash Flow and Debt**: INBS has a negative free cash flow of $11.54 million and a low debt-to-equity ratio of 0.05, which is a positive sign as it indicates that the company is not overly leveraged. However, the negative free cash flow is a concern as it suggests that the company is not generating enough cash to cover its operations.

4. **Market Sentiment and Analyst Ratings**: Analysts expect INBS to incur a final loss in 2025 before generating positive profits, with an average annual growth rate of 78% expected. While this growth rate is high, it may be unrealistic, and the company may become profitable later than anticipated if the growth rate is lower than expected.
5. **Future Outlook**: INBS is developing non-invasive diagnostic tests and is expected to benefit from the growing biotechnology market, which is predicted to reach USD 4.25 trillion by 2033, growing at a CAGR of 11.8% from 2024 to 2033. However, the company's current financial performance and valuation metrics should be considered before investing.

In conclusion, while INBS is working on innovative technologies and is expected to benefit from the growing biotechnology market, the current financial performance, negative free cash flow, and high valuation metrics make it a risky investment. Potential investors should exercise caution and consider these factors before making a decision.